From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Study Identifies Two Measures of Tumor Burden for Risk Stratification of Patients With Hodgkin...

The presence of bulky disease is commonly used as one factor in categorizing patients with early-stage Hodgkin lymphoma (HL) as having either favorable or...
WIB_icon

Examining Infection Risk in Patients Treated With Anti-CD19 CAR T-Cell Therapies

Management of the toxicities commonly associated with chimeric antigen receptor (CAR) T-cell therapy, including cytokine release syndrome (CRS) and neurotoxicity, can require stays in...
WIB_icon

Is Radiotherapy Necessary for Treating DLBCL With R-CHOP?

The combination of involved-field radiotherapy (RT) and chemotherapy has been considered a standard treatment for patients with early-stage diffuse large B-cell lymphoma (DLCBL), but...

High Rates of Depression Resulting in Higher Health-Care Costs in Patients With Sickle Cell...

Depression is approximately five times more prevalent in patients with sickle cell disease (SCD) than in the general population, and it is significantly associated...

Study Finds Cancer Risk is Higher Than Expected Among Patients With Pregnancy-Related VTE

Venous thromboembolism (VTE) is associated with an increased prevalence of occult cancer. As pregnancy is also associated with an increased risk of VTE, it...

Clinical Trials Review Confirms Poor Outcomes for Patients With Refractory NHL

In an analysis of patient-level data from four large trial cohorts, researchers reported that patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)...

TP53 Mutations Identify Patients With “Highly Aggressive” Mantle Cell Lymphoma

Patients with TP53-mutated mantle cell lymphoma (MCL) have poor overall survival (OS), compared with patients without the mutation. In an analysis of two trials...

Comparing Brentuximab Vedotin–Based Frontline Regimens for Hodgkin Lymphoma in Older Patients

The combinations of brentuximab vedotin (BV) and dacarbazine or BV and bendamustine both led to high objective response rates (ORR) in older patients with...
WIB_icon

Predicting the Risk and Severity of Cytokine Release Syndrome in Patients Receiving CAR T-Cell...

While treatment with CD19-directed chimeric antigen receptor (CAR) T cells has demonstrated impressive response rates of over 80% in select patients with B-cell malignancies,...
WIB_icon

Adding Rituximab to Corticosteroids and Cyclosporine A in Patients With cGVHD Improves ORR

Standard firstline treatment for chronic graft-versus-host disease (cGVHD) includes corticosteroids and cyclosporine A, but disease control often requires long-term immunosuppressive treatment, which impairs patients’...
Advertisement

Current Issue

December 2017, Volume 3, Issue 14

This issue features physicians' insights on gun control, the use of cannabis for symptom relief, and more.